

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ASCENDIS PHARMA A/S,
Petitioner,

v.

BIOMARIN PHARMACEUTICAL INC.,
Patent Owner.

Case PGR2026-00013
Patent No. 12,233,106 B2

PATENT OWNER'S CURRENT LIST OF EXHIBITS

LIST OF EXHIBITS

Exhibit No.	Description	Previously Submitted
2001	USITC Inv. No. 337-TA-1447, Order No. 25: Amending Procedural Schedule (December 16, 2025), EDIS Doc. ID. 866614	
2002	USITC Investigations Database System, Status of Investigation 337-1447, https://ids.usitc.gov/case/8276/investigation/8728 (last accessed January 20, 2026)	
2003	RESERVED	
2004	U.S. Reissue Patent No. 48,267	
2005	USITC Inv. No. 337-TA-1447, Amended Complaint (August 22, 2025), EDIS Doc. ID. 860269	
2006	USITC Inv. No. 337-TA-1447, Disputed and Agreed Claim Constructions (September 23, 2025), EDIS Doc. ID 862675	
2007	RESERVED	
2008	RESERVED	
2009	RESERVED	
2010	RESERVED	
2011	USITC Inv. No. 337-TA-1447, Order No. 15: Initial Determination Granting Complainant's (1) Motion to Declassify and (2) Motion to Amend the Complaint and Notice of Investigation (August 14, 2025), EDIS Doc. ID. 861044	
2012	FDA Guidance for Industry, General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products (July 2022) at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-clinical-pharmacology-considerations-neonatal-studies-drugs-and-biological-products-guidance , and https://www.fda.gov/media/129532/download (last accessed January 27, 2026)	
2013	Sian Gaze, Best Practice for Medicines Use in Neonates, Pharmaceutical Journal (May 7, 2024) at https://pharmaceutical-journal.com/article/ld/best-	

	practice-for-medicines-use-in-neonates (last accessed January 27, 2026)	
2014	March 31, 2025 Ascendis Press Release at https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-submits-us-nda-transcon-cnp-navepegritide-treatment (last accessed January 27, 2026)	
2015	November 25, 2025 Ascendis Press Release at https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-announces-extension-fda-review-period-transcon-cnp (last accessed January 27, 2026)	
2016	Clinical Trial NCT06079398 (ASND0030) at https://clinicaltrials.gov/study/NCT06079398 (last accessed January 27, 2026)	
2017	Savarirayan (2024), <i>Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial</i> , Lancet Child Adolesc. Health, 8(1):40-50	
2018	USITC Inv. No. 337-TA-1447, Commission Investigative Staff's Claim Construction Brief (December 1, 2025), EDIS Doc. ID. 866257	

Dated: February 3, 2026

Respectfully submitted,

By: /Naveen Modi/
Naveen Modi
Reg. No. 46,224

CERTIFICATE OF SERVICE

I certify that I caused to be served on the counsel identified below a true and correct copy of the foregoing Patent Owner's Current List of Exhibits by electronic means on February 3, 2026:

David H. Homan (dholman-PTAB@sternekessler.com)
Pratibha Khanduri (pkhanduri-PTAB@sternekessler.com)
Olga A. Partington (opartington-PTAB@sternekessler.com)
Eric Steffe (esteffe-PTAB@sternekessler.com)
PTAB@sternekessler.com

By: /Naveen Modi/
Naveen Modi
Reg. No. 46,224